Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer

Celestia S. Higano, Tomasz (Tom) Beer, Mary Ellen Taplin, Eleni Efstathiou, Mohammad Hirmand, David Forer, Howard I. Scher

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Background Given that some patients with castration-resistant prostate cancer (CRPC) have shown extended responses to the androgen receptor inhibitor enzalutamide, long-term safety of this drug is of interest. Objective To evaluate the long-term safety and antitumor activity of enzalutamide in CRPC patients. Design, setting, and participants This phase 1-2 study evaluated enzalutamide in 140 CRPC patients with and without prior chemotherapy. Initial findings were published in 2010. We report updated results from an additional 17-mo follow-up for antitumor activity and >4 yr for safety. Intervention Patients received 30-600 mg/d oral enzalutamide. During long-term dosing, all patients were switched first to the maximum tolerated dose of 240 mg/d and then to the phase 3 dose of 160 mg/d. Outcome measurements and statistical analysis Safety was assessed regularly. The Kaplan-Meier method was used to estimate the distributions of time to prostate-specific antigen (PSA) progression and time to radiographic progression. Results and limitations The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs. Fatigue of any grade was the most common dose-dependent AE, experienced by 70% of patients, with 14% of patients reporting grade 3/4 fatigue. The median time to PSA progression was not reached for chemotherapy-naive patients and was 45 wk for postchemotherapy patients; the corresponding median time to radiographic progression was 56 wk and 25 wk. Conclusions Enzalutamide showed durable antitumor activity in chemotherapy-naive and postchemotherapy patients, and was well tolerated, even in patients treated for 4 yr. Patient summary Enzalutamide was active against prostate cancer and was well tolerated, even for up to 4 yr of treatment, supporting its potential for long-term use in men with prostate cancer. Fatigue was the most common side effect, occurring at varying degrees of severity in most patients.

    Original languageEnglish (US)
    Pages (from-to)795-801
    Number of pages7
    JournalEuropean Urology
    Volume68
    Issue number5
    DOIs
    StatePublished - Nov 1 2015

    Fingerprint

    docetaxel
    Castration
    Prostatic Neoplasms
    Safety
    Fatigue
    Prostate-Specific Antigen
    Drug Therapy
    MDV 3100

    Keywords

    • Androgen receptor inhibitor
    • Castration-resistant prostate cancer
    • Enzalutamide
    • Long-term follow-up
    • MDV3100
    • Tolerability

    ASJC Scopus subject areas

    • Urology

    Cite this

    Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. / Higano, Celestia S.; Beer, Tomasz (Tom); Taplin, Mary Ellen; Efstathiou, Eleni; Hirmand, Mohammad; Forer, David; Scher, Howard I.

    In: European Urology, Vol. 68, No. 5, 01.11.2015, p. 795-801.

    Research output: Contribution to journalArticle

    Higano, Celestia S. ; Beer, Tomasz (Tom) ; Taplin, Mary Ellen ; Efstathiou, Eleni ; Hirmand, Mohammad ; Forer, David ; Scher, Howard I. / Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. In: European Urology. 2015 ; Vol. 68, No. 5. pp. 795-801.
    @article{594f545af4f14dae9e2121b002ed95f7,
    title = "Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer",
    abstract = "Background Given that some patients with castration-resistant prostate cancer (CRPC) have shown extended responses to the androgen receptor inhibitor enzalutamide, long-term safety of this drug is of interest. Objective To evaluate the long-term safety and antitumor activity of enzalutamide in CRPC patients. Design, setting, and participants This phase 1-2 study evaluated enzalutamide in 140 CRPC patients with and without prior chemotherapy. Initial findings were published in 2010. We report updated results from an additional 17-mo follow-up for antitumor activity and >4 yr for safety. Intervention Patients received 30-600 mg/d oral enzalutamide. During long-term dosing, all patients were switched first to the maximum tolerated dose of 240 mg/d and then to the phase 3 dose of 160 mg/d. Outcome measurements and statistical analysis Safety was assessed regularly. The Kaplan-Meier method was used to estimate the distributions of time to prostate-specific antigen (PSA) progression and time to radiographic progression. Results and limitations The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs. Fatigue of any grade was the most common dose-dependent AE, experienced by 70{\%} of patients, with 14{\%} of patients reporting grade 3/4 fatigue. The median time to PSA progression was not reached for chemotherapy-naive patients and was 45 wk for postchemotherapy patients; the corresponding median time to radiographic progression was 56 wk and 25 wk. Conclusions Enzalutamide showed durable antitumor activity in chemotherapy-naive and postchemotherapy patients, and was well tolerated, even in patients treated for 4 yr. Patient summary Enzalutamide was active against prostate cancer and was well tolerated, even for up to 4 yr of treatment, supporting its potential for long-term use in men with prostate cancer. Fatigue was the most common side effect, occurring at varying degrees of severity in most patients.",
    keywords = "Androgen receptor inhibitor, Castration-resistant prostate cancer, Enzalutamide, Long-term follow-up, MDV3100, Tolerability",
    author = "Higano, {Celestia S.} and Beer, {Tomasz (Tom)} and Taplin, {Mary Ellen} and Eleni Efstathiou and Mohammad Hirmand and David Forer and Scher, {Howard I.}",
    year = "2015",
    month = "11",
    day = "1",
    doi = "10.1016/j.eururo.2015.01.026",
    language = "English (US)",
    volume = "68",
    pages = "795--801",
    journal = "European Urology",
    issn = "0302-2838",
    publisher = "Elsevier",
    number = "5",

    }

    TY - JOUR

    T1 - Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer

    AU - Higano, Celestia S.

    AU - Beer, Tomasz (Tom)

    AU - Taplin, Mary Ellen

    AU - Efstathiou, Eleni

    AU - Hirmand, Mohammad

    AU - Forer, David

    AU - Scher, Howard I.

    PY - 2015/11/1

    Y1 - 2015/11/1

    N2 - Background Given that some patients with castration-resistant prostate cancer (CRPC) have shown extended responses to the androgen receptor inhibitor enzalutamide, long-term safety of this drug is of interest. Objective To evaluate the long-term safety and antitumor activity of enzalutamide in CRPC patients. Design, setting, and participants This phase 1-2 study evaluated enzalutamide in 140 CRPC patients with and without prior chemotherapy. Initial findings were published in 2010. We report updated results from an additional 17-mo follow-up for antitumor activity and >4 yr for safety. Intervention Patients received 30-600 mg/d oral enzalutamide. During long-term dosing, all patients were switched first to the maximum tolerated dose of 240 mg/d and then to the phase 3 dose of 160 mg/d. Outcome measurements and statistical analysis Safety was assessed regularly. The Kaplan-Meier method was used to estimate the distributions of time to prostate-specific antigen (PSA) progression and time to radiographic progression. Results and limitations The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs. Fatigue of any grade was the most common dose-dependent AE, experienced by 70% of patients, with 14% of patients reporting grade 3/4 fatigue. The median time to PSA progression was not reached for chemotherapy-naive patients and was 45 wk for postchemotherapy patients; the corresponding median time to radiographic progression was 56 wk and 25 wk. Conclusions Enzalutamide showed durable antitumor activity in chemotherapy-naive and postchemotherapy patients, and was well tolerated, even in patients treated for 4 yr. Patient summary Enzalutamide was active against prostate cancer and was well tolerated, even for up to 4 yr of treatment, supporting its potential for long-term use in men with prostate cancer. Fatigue was the most common side effect, occurring at varying degrees of severity in most patients.

    AB - Background Given that some patients with castration-resistant prostate cancer (CRPC) have shown extended responses to the androgen receptor inhibitor enzalutamide, long-term safety of this drug is of interest. Objective To evaluate the long-term safety and antitumor activity of enzalutamide in CRPC patients. Design, setting, and participants This phase 1-2 study evaluated enzalutamide in 140 CRPC patients with and without prior chemotherapy. Initial findings were published in 2010. We report updated results from an additional 17-mo follow-up for antitumor activity and >4 yr for safety. Intervention Patients received 30-600 mg/d oral enzalutamide. During long-term dosing, all patients were switched first to the maximum tolerated dose of 240 mg/d and then to the phase 3 dose of 160 mg/d. Outcome measurements and statistical analysis Safety was assessed regularly. The Kaplan-Meier method was used to estimate the distributions of time to prostate-specific antigen (PSA) progression and time to radiographic progression. Results and limitations The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs. Fatigue of any grade was the most common dose-dependent AE, experienced by 70% of patients, with 14% of patients reporting grade 3/4 fatigue. The median time to PSA progression was not reached for chemotherapy-naive patients and was 45 wk for postchemotherapy patients; the corresponding median time to radiographic progression was 56 wk and 25 wk. Conclusions Enzalutamide showed durable antitumor activity in chemotherapy-naive and postchemotherapy patients, and was well tolerated, even in patients treated for 4 yr. Patient summary Enzalutamide was active against prostate cancer and was well tolerated, even for up to 4 yr of treatment, supporting its potential for long-term use in men with prostate cancer. Fatigue was the most common side effect, occurring at varying degrees of severity in most patients.

    KW - Androgen receptor inhibitor

    KW - Castration-resistant prostate cancer

    KW - Enzalutamide

    KW - Long-term follow-up

    KW - MDV3100

    KW - Tolerability

    UR - http://www.scopus.com/inward/record.url?scp=84942984668&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84942984668&partnerID=8YFLogxK

    U2 - 10.1016/j.eururo.2015.01.026

    DO - 10.1016/j.eururo.2015.01.026

    M3 - Article

    VL - 68

    SP - 795

    EP - 801

    JO - European Urology

    JF - European Urology

    SN - 0302-2838

    IS - 5

    ER -